Rahamathullah, M M (2021) Effect of Super Disintegrating Agents on Imantinib In Vitro Drug Release study using Kinetic Model. Masters thesis, Padmavathi College of Pharmacy, Dharmapuri.
|
Text
261110421rahamathullah.pdf Download (2MB) | Preview |
Abstract
Imatinib is one of the first cancer therapies that has shown a potential for a novel approachin cancer treatment. Imatinib represents a therapeutic breakthrough as a targeted therapy in the form of selective tyrosine kinase inhibitors (TKIs) specifically BCR-ABL, c- KIT, PDGFRA. It has become the first line drug in management of several cancers. Apart from itsremarkable success in CML, it has also shown promising results in the treatment of gastro- intestinal stromal tumors, clonal eosinophilic disorders, Philadelphia chromosome positive acute lymphatic leukemia and in steroid-refractory chronic graft versus-host disease because of its anti-PDGFR action. Introduction of Imatinib has radically improved the outcome of patients and has geared up further research into development of designer drugs with molecular targets. The first clinical trial of Imatinib took place in 1998 and the drug received FDA approval in May 2001. Lyndon, Druker, and the other colleagues were awarded the Lasker-DeBakey Clinical Medical Research Award in 2009 for “converting a fatal cancer into a manageable condition” and the Japan Prize in 2012 for their part in “the development of a new therapeutic drug targeting cancer-specific molecules.” Encouraged by the success of Imatinib in treating CML patients, scientists explored its effect in other cancers and it was found to produce a similar miracle effect in other cancers where tyrosine kinases were overexpressed. CONCLUSION: It is evident from the result of formulation F9 which is formulated with sodium starch glycolate (10mg) shows maximum and better release at the end of 30min, when comparatively with F1-F8. This may be due to their rapid swelling mechanism, less particle size, and also the cost of sodium starch glycolate is less when compared to crospovidone, croscarmellose sodium. Thus the work proves that sodium starch glycolate is better super disintegrating agent in the In-vitro drug release and it is cost effective. The formulation F1-F9 exhibited fickian drug release mechanism.
| Item Type: | Thesis (Masters) |
|---|---|
| Additional Information: | 261910852 |
| Uncontrolled Keywords: | Application, Cocrystal Technique, Enhancement, Solubility, Spironolactone, Drug Release, UV Spectrophotometric Method. |
| Subjects: | PHARMACY > Pharmaceutics |
| Depositing User: | Subramani R |
| Date Deposited: | 01 Nov 2022 16:35 |
| Last Modified: | 01 Nov 2022 16:35 |
| URI: | http://repository-tnmgrmu.ac.in/id/eprint/20880 |
Actions (login required)
 |
View Item |
